Filing Flows › Health Care › Sensus Healthcare (SRTS)
Sensus Healthcare (SRTS) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Sensus Healthcare (SRTS) Q2 2026 earnings results →
Q2 2026 Revenue down 69% year over year to $2.3M · 382¢ of every $1 of revenue lost · operating margin -138.9%
Sensus Healthcare made $2.3M in Q2 2026 (-69% Y/Y): Product $1.2M, Service $395K, Service Revenue $330K. Operating margin -138.9%, net loss $8.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $2.3M in Q2 2026, down 69% year over year and down 33% from the previous quarter. Product was the largest line at 54% of revenue. Product lost $4.1M year over year (down 77%), 83% of the total change.
Gross margin was 33.6%, down 6.1 points from Q2 2025. Operating costs exceeded revenue by $3.2M, an operating margin of -138.9%. Operating expenses fell 19% while revenue fell 69%. The quarter ended with a net loss of $8.7M, wider than the previous quarter's $2.6M loss.
Operating cash flow was −$3.1M. Non-cash charges added back $86K of depreciation and $70K of share-based compensation. Working capital and other items added $5.5M. Capital expenditures of $8K exceeded it, leaving free cash flow of −$3.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $2.3M | -69% | -138.9% | −$8.7M | −$3.1M |
| Q1 2026 | 10-Q | May 13, 2026 | $3.4M | -59% | -128.4% | −$2.6M | −$3.8M |
| Q4 2025 | 10-K | Mar 4, 2026 | $4.9M | -62% | -63.7% | −$3.2M | −$2.2M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $6.9M | -22% | -37.3% | −$943K | $2.3M |
| Q2 2025 | 10-Q | Aug 12, 2025 | $7.3M | -21% | -26.6% | −$1.0M | $3.1M |
| Q1 2025 | 10-Q | May 15, 2025 | $8.3M | -22% | -31.7% | −$2.6M | −$2.7M |
| Q4 2024 | 10-K | Mar 5, 2025 | $13.1M | +4% | 13.2% | $1.5M | −$827K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Sensus Healthcare
Sensus Healthcare, Inc. (together, with its subsidiaries, Sensus Medical Devices Ltd. and Sensus Healthcare Services, LLC, unless the context otherwise indicates, “Sensus,” “we,” “us,” “our,” or the “Company”) is a medical device company committed to providing highly effective, non-invasive treatments for non-melanoma skin cancer (NMSC) and post-surgical keloid scar prevention. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (“SRT”), which is based on decades of dedicated research and development, and has successfully incorporated SRT into a portfolio of treatment devices: the SRT-100 TM , SRT-100+ TM and SRT-100 Vision TM . To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions of close to one-million patients around the world.
In its own words, from its 10-K, filed Mar 4, 2026.
Sensus Healthcare against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -69% against the peers' median +5%. Operating margin: -138.9% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| SRTS Sensus Healthcare | Q2 2026 | $2.3M | -69% | -138.9% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Sensus Healthcare 10-Q on SEC EDGAR · CIK 1494891 · Surgical & Medical Instruments & Apparatus
13F: who owns SRTS and who is buying
More on SRTS
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results